William P. Kane Jr - Feb 6, 2023 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role: Chief Commercial Officer
Signature: /s/ Troy Ignelzi, Attorney-in-fact
Stock symbol: KRTX
Transactions as of: Feb 6, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/7/2023, 05:16 PM
Previous filing: Aug 18, 2021
Next filing: Dec 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Award	$0	+17.7K		$0.00	17.7K	Feb 6, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Stock Option (Right to Buy)	Award	$0	+29.9K		$0.00	29.9K	Feb 6, 2023	Common Stock	29.9K	$192.15	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 6, 2024, subject to continued service through such dates.
F2	25% of this option shall vest on February 6, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.